Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor

Mimuro, Jun; Koike, Yasunori; Sumi, Yôichi; Aoki, Nobuo

doi:10.1182/blood.v69.2.446.bloodjournal692446

Cited by 58 publications

(26 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prothrombin fragment 1 +2 (F1+2) was measured by a sandwich ELISA (Enzygnost-F1+2, Behringwerke AG, Marburg, Germany) [20]. Plasmin-a,-plasmin inhibitor complex (PIC) was measured by a one-step sandwich ELISA (PIC test, Teijin Ltd., Tokyo, Japan) using polyclonal antiplasminogen antibody-coated polystyrene balls and peroxidase-conjugated monoclonal antibody against a,-plasmin inhibitor [21,22]. Activated partial thromboplastin time (APTT), prothrombin time, fibrinogen, and platelet count were measured by standard methods.…”

Section: Assay Methodsmentioning

confidence: 99%

Tissue factor in plasma of patients with disseminated intravascular coagulation

et al. 1994

View full text Add to dashboard Cite

Recently it has been shown that tissue factor (TF), an important trigger for initiating blood coagulation, is present in the circulating plasma. In order to assess the clinical implications of TF in plasma, plasma concentration of TF was quantitated in 65 patients with disseminated intravascular coagulation (DIC). The mean concentration of plasma TF was elevated in patients with DIC at presentation as compared with healthy subjects (446 +/- SD 536 pg/ml vs. 138 +/- 51 pg/ml, P < 0.001). Abnormally high levels were found only in 46.2% of the patients, predominantly in patients with non-hematological solid tumors and acute leukemia. Plasma TF did not correlate with hemostatic markers of DIC such as thrombin-antithrombin III complex, prothrombin fragment 1 + 2, plasma-alpha 2-plasmin inhibitor complex, FDP, D-dimer, or fibrinogen. Serial determinations of plasma TF demonstrated that plasma TF changes roughly in parallel with the course of DIC in most patients with elevated TF at presentation of DIC. These findings suggest that plasma TF is potentially valuable for monitoring the progress of DIC in a limited population of patients.

show abstract

Section: Assay Methodsmentioning

confidence: 99%

Tissue factor in plasma of patients with disseminated intravascular coagulation

et al. 1994

View full text Add to dashboard Cite

show abstract

“…Human t-PA, PAI-1, and vitronectin were purified as described previously. 11,12 Human u-PA was a gift from Mochida Pharmaceutical (Tokyo, Japan). Monospecific antisera against u-PA, t-PA, and PAI-1 were prepared in rabbits as previously described 11 and immunopurified with each antigen immobilized on Sepharose 4B.…”

Section: Preparation and Characterization Of The Monoclonalmentioning

confidence: 99%

“…11,12 Human u-PA was a gift from Mochida Pharmaceutical (Tokyo, Japan). Monospecific antisera against u-PA, t-PA, and PAI-1 were prepared in rabbits as previously described 11 and immunopurified with each antigen immobilized on Sepharose 4B. Monoclonal antibodies against t-PA (JTA-1), u-PA (JSUK-2 and JSUK-5), PAI-1 (JTAI-3 and JTAI-4), and vitronectin (JFV-1, JYV-1) were prepared by the conventional method with BALB/c mice as previously described 13 and immunopurified as described above.…”

Section: Preparation and Characterization Of The Monoclonalmentioning

confidence: 99%

Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck

et al. 1997

View full text Add to dashboard Cite

Background Plasminogen activators (PAs) and their inhibitors are thought to play an important role in tumor invasion and metastasis. However, there have been few reports in which histologic localization of PAs has been demonstrated in head and neck tumors. Methods We examined the patterns of expression of urokinase‐type plasminogen activator (u‐PA), tissue‐type plasminogen activator (t‐PA), plasminogen activator inhibitor 1 (PAI‐1), and vitronectin in head and neck squamous cell carcinomas using immunohistochemical techniques. We also studied the correlation between the immunohistologic expression of these fibrinolytic proteins and the clinical staging of the tumor. Results Of 28 tumor specimens, 15 (54%) showed immunoreactivity for u‐PA; 8 (36%), for t‐PA; and 23 ( 82%), for PAI‐1. There was a significant correlation between PAI‐1 expression and the extent of the primary tumor. Conclusions The present study demonstrates the existence and possible pathophysiologic significance of u‐PA and PAI‐1 in squamous cell carcinomas of the head and neck. © 1997 John Wiley & Sons, Inc. Head Neck 19: 611–616, 1997.

show abstract

“…A previous study [5] has shown that early diagnosis and treatment of DIC improve clinical outcome. Although the usefulness of hemostatic molecular markers such as thrombin-antithrombin complex (TAT) [6], plasmin plasmininhibitor complex (PPIC) [7], and soluble fibrin (SF) [8] for the early diagnosis of DIC has been reported, such measurements are expensive and time-consuming. In Japan, DIC patients are usually treated with heparin [9] or with gabexate mesilate (FOY), a synthetic protease inhibitor [10] that inhibits the activity of thrombin, Factor Xa, plasmin, and plasma kallikrein.…”

Section: Introductionmentioning

confidence: 99%

High plasma fibrinogen level is associated with poor clinical outcome in DIC patients

et al. 2002

View full text Add to dashboard Cite

We measured the plasma level of fibrinogen in 560 patients with disseminated intravascular coagulation (DIC) and evaluated its relationship with outcome and with other hemostatic markers. Forty-seven percent of patients had >200 mg/dL of plasma fibrinogen and 24% had <100 mg/dl of plasma fibrinogen, suggesting that plasma fibrinogen level is not a sensitive marker for DIC. In our analysis of outcome and plasma fibrinogen levels, the rate of death was high in leukemia/lymphoma patients with high fibrinogen concentration, but no significant difference in outcome was observed in relation to plasma fibrinogen concentration in non-leukemia/lymphoma patients with DIC. Among patients with leukemia/lymphoma, the frequency of organ failure was markedly high in patients with high plasma levels of fibrinogen. Among patients without leukemia/lymphoma, the frequency of organ failure increased concomitantly with the increase in plasma fibrinogen levels. The international normalized ratio was significantly increased in leukemia/ lymphoma patients with low fibrinogen. FDP levels were slightly increased in patients with low fibrinogen. Platelet count was significantly low in patients without leukemia/ lymphoma with high fibrinogen. DIC score increased concomitantly with the reduction in plasma fibrinogen levels. Plasma levels of thrombomodulin and tissue factor were significantly high in patients with high fibrinogen levels. Plasma levels of antiplasmin and plasminogen were significantly decreased in patients with low fibrinogen. Plasma levels of plasmin plasmin-inhibitor complex and tissue type plasminogen activator/ plasminogen activator inhibitor-1 complex (PAI-I) were significantly higher in patients with low fibrinogen than in those with high fibrinogen. Plasma levels of PAI-I and IL-6 were significantly higher in patients with high fibrinogen than in those with low fibrinogen. Patients with high fibrinogen levels showed less activation of secondary fibrinolysis, which might explain the occurrence of organ failure and poor outcome. Am. J. Hematol. 72:1-7, 2003.

show abstract

Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor

Cited by 58 publications

References 12 publications

Tissue factor in plasma of patients with disseminated intravascular coagulation

Tissue factor in plasma of patients with disseminated intravascular coagulation

Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck

High plasma fibrinogen level is associated with poor clinical outcome in DIC patients

Contact Info

Product

Resources

About